Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of ...

Scientists with the Fralin Biomedical Research Institute at VTC have created an engineered model of the supportive tissue ...

KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

Vitiligo Awareness Month and World Vitiligo Day aim to educate the public about the autoimmune skin condition's complex ...

ElAbd, H., Pesesky, M. et al.: T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis. Nat Med (2025). https://doi.org/10.1038/s41591-025-03692-w ...

Indian American immunologist selected as next Chair of University of Rochester Medical Center Department of Microbiology and Immunology ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Presentation Date and Time: June 18, 2025, at 11:45 AM ET Location : ...

The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK ...